Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis

Immune checkpoint inhibitors (ICI) is a rapidly evolving treatment modality for stage IV non-small cell lung cancer (NSCLC). Concomitant proton pump inhibitor (PPI) use can potentially reduce the clinical efficacy of ICIs; however, the consensus in recent literature has been conflicting. This study...

Full description

Saved in:
Bibliographic Details
Published in:Annals of medicine and surgery 2022-06, Vol.78, p.103752-103752, Article 103752
Main Authors: Dar, Sophia, Merza, Nooraldin, Rahim, Mehek, Qatani, Ahmad, Varughese, Tony, Mohammad, Asna, Masood, Fahad, Reza, Fizza, Shucenwan, Almas, Talal, Ellahi, Aayat, Ligresti, Rosario
Format: Article
Language:English
Subjects:
Cancer
Immune checkpoint inhibitors
Non- small cell lung cancer
Proton pump inhibitor
Survival outcomes
Systematic Review / Meta-analysis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c455t-358431ee546f21e031947ed63438e3fc3d0a731ae1c9a9b09c93283f05085fb3
cites
container_end_page 103752
container_issue
container_start_page 103752
container_title Annals of medicine and surgery
container_volume 78
creator Dar, Sophia
Merza, Nooraldin
Rahim, Mehek
Qatani, Ahmad
Varughese, Tony
Mohammad, Asna
Masood, Fahad
Reza, Fizza
Shucenwan
Almas, Talal
Ellahi, Aayat
Ligresti, Rosario
description Immune checkpoint inhibitors (ICI) is a rapidly evolving treatment modality for stage IV non-small cell lung cancer (NSCLC). Concomitant proton pump inhibitor (PPI) use can potentially reduce the clinical efficacy of ICIs; however, the consensus in recent literature has been conflicting. This study aims to analyze overall survival (OS) and progression-free survival (PFS) outcomes in patients with NSCLC on ICI and concomitant PPI therapy. A literature search was done in 3 databases (Pubmed/Medline, Embase, and Cochrane Central). All studies meeting the inclusion criteria assessing the impact of PPIs on the efficacy of ICI in NSCLC patients were systematically identified. A random-effects network meta-analysis evaluated OS and PFS in the two arms. Four studies with 2,940 patients are included in our analysis. ICI usage alone was associated with significantly better OS [HR = 1.46, 95% CI = 1.27–1.67, P 
doi_str_mv 10.1016/j.amsu.2022.103752
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9119820</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S204908012200512X</els_id><sourcerecordid>2668220378</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-358431ee546f21e031947ed63438e3fc3d0a731ae1c9a9b09c93283f05085fb3</originalsourceid><addsrcrecordid>eNp9kctu3CAUhq2qVROleYEuKpbdeMrF-FJVlaKol0iRuskencGHDFMDLuBE8yB932JNGk033QAHvvMD_19VbxndMMraD_sNuLRsOOW8bIhO8hfVOafNUNOespcn67PqMqU9pZRRKdq2f12dCdmWsmvPq983bgadSTBkjiEHX8-Lm4n1O7u1OcREgid5hwSNsRr0YSWtc4tHoneof87B-nzKW098kUkOpoloLMO0-HuiwWuMH8kVSYeU0UG2mkR8sPhIwI_EYYYaPEyHZNOb6pWBKeHl03xR3X39cnf9vb798e3m-uq21o2UuRaybwRDlE1rOEMq2NB0OLaiET0Ko8VIoRMMkOkBhi0d9CB4LwyVtJdmKy6qz0fZedk6HDX6HGFSc7QO4kEFsOrfE2936j48qIGxoee0CLx_Eojh14IpK2fT-mfwGJakeLGbF67rC8qPqI4hpYjm-RpG1Zqo2qs1UbUmqo6JlqZ3pw98bvmbXwE-HQEsLhUvo0raYnF6tBF1VmOw_9P_A047tS8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2668220378</pqid></control><display><type>article</type><title>Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis</title><source>ScienceDirect (Online service)</source><source>PubMed Central</source><creator>Dar, Sophia ; Merza, Nooraldin ; Rahim, Mehek ; Qatani, Ahmad ; Varughese, Tony ; Mohammad, Asna ; Masood, Fahad ; Reza, Fizza ; Shucenwan ; Almas, Talal ; Ellahi, Aayat ; Ligresti, Rosario</creator><creatorcontrib>Dar, Sophia ; Merza, Nooraldin ; Rahim, Mehek ; Qatani, Ahmad ; Varughese, Tony ; Mohammad, Asna ; Masood, Fahad ; Reza, Fizza ; Shucenwan ; Almas, Talal ; Ellahi, Aayat ; Ligresti, Rosario</creatorcontrib><description>Immune checkpoint inhibitors (ICI) is a rapidly evolving treatment modality for stage IV non-small cell lung cancer (NSCLC). Concomitant proton pump inhibitor (PPI) use can potentially reduce the clinical efficacy of ICIs; however, the consensus in recent literature has been conflicting. This study aims to analyze overall survival (OS) and progression-free survival (PFS) outcomes in patients with NSCLC on ICI and concomitant PPI therapy. A literature search was done in 3 databases (Pubmed/Medline, Embase, and Cochrane Central). All studies meeting the inclusion criteria assessing the impact of PPIs on the efficacy of ICI in NSCLC patients were systematically identified. A random-effects network meta-analysis evaluated OS and PFS in the two arms. Four studies with 2,940 patients are included in our analysis. ICI usage alone was associated with significantly better OS [HR = 1.46, 95% CI = 1.27–1.67, P &lt; 0.00001] and PFS [HR = 1.31, 95% CI = 1.17–1.47, P &lt; 0.00001] when compared to concomitant PPI and ICI therapy. The concomitant use of PPIs during ICI therapy significantly worsens clinical outcomes with shorter OS and increased risk of disease progression in patients with NSCLC. •Immune checkpoint inhibitors are a rapidly evolving treatment regime used for various cancer therapies. The role of other medications in their effectiveness remains conflicted. Proton Pump Inhibitors are one of the most commonly prescribed medications and are particularly often prescribed to cancer patients.•Our study finds that Proton Pump Inhibitors worsen the outcomes of overall survival and increase risk of disease progression in Non-Small Cell Lung Carcinoma.•We hope that this study will enlighten providers to use proton pump inhibitors more judiciously in patients with Non-Small Cell Lung Carcinoma.</description><identifier>ISSN: 2049-0801</identifier><identifier>EISSN: 2049-0801</identifier><identifier>DOI: 10.1016/j.amsu.2022.103752</identifier><identifier>PMID: 35600176</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Cancer ; Immune checkpoint inhibitors ; Non- small cell lung cancer ; Proton pump inhibitor ; Survival outcomes ; Systematic Review / Meta-analysis</subject><ispartof>Annals of medicine and surgery, 2022-06, Vol.78, p.103752-103752, Article 103752</ispartof><rights>2022 The Authors</rights><rights>2022 The Authors.</rights><rights>2022 The Authors 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-358431ee546f21e031947ed63438e3fc3d0a731ae1c9a9b09c93283f05085fb3</citedby><orcidid>0000-0002-8867-600X ; 0000-0002-5687-9371 ; 0000-0001-9697-7542 ; 0000-0003-0242-6008 ; 0000-0002-5874-3312 ; 0000-0002-2843-9432</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9119820/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S204908012200512X$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,3536,27901,27902,45756,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35600176$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dar, Sophia</creatorcontrib><creatorcontrib>Merza, Nooraldin</creatorcontrib><creatorcontrib>Rahim, Mehek</creatorcontrib><creatorcontrib>Qatani, Ahmad</creatorcontrib><creatorcontrib>Varughese, Tony</creatorcontrib><creatorcontrib>Mohammad, Asna</creatorcontrib><creatorcontrib>Masood, Fahad</creatorcontrib><creatorcontrib>Reza, Fizza</creatorcontrib><creatorcontrib>Shucenwan</creatorcontrib><creatorcontrib>Almas, Talal</creatorcontrib><creatorcontrib>Ellahi, Aayat</creatorcontrib><creatorcontrib>Ligresti, Rosario</creatorcontrib><title>Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis</title><title>Annals of medicine and surgery</title><addtitle>Ann Med Surg (Lond)</addtitle><description>Immune checkpoint inhibitors (ICI) is a rapidly evolving treatment modality for stage IV non-small cell lung cancer (NSCLC). Concomitant proton pump inhibitor (PPI) use can potentially reduce the clinical efficacy of ICIs; however, the consensus in recent literature has been conflicting. This study aims to analyze overall survival (OS) and progression-free survival (PFS) outcomes in patients with NSCLC on ICI and concomitant PPI therapy. A literature search was done in 3 databases (Pubmed/Medline, Embase, and Cochrane Central). All studies meeting the inclusion criteria assessing the impact of PPIs on the efficacy of ICI in NSCLC patients were systematically identified. A random-effects network meta-analysis evaluated OS and PFS in the two arms. Four studies with 2,940 patients are included in our analysis. ICI usage alone was associated with significantly better OS [HR = 1.46, 95% CI = 1.27–1.67, P &lt; 0.00001] and PFS [HR = 1.31, 95% CI = 1.17–1.47, P &lt; 0.00001] when compared to concomitant PPI and ICI therapy. The concomitant use of PPIs during ICI therapy significantly worsens clinical outcomes with shorter OS and increased risk of disease progression in patients with NSCLC. •Immune checkpoint inhibitors are a rapidly evolving treatment regime used for various cancer therapies. The role of other medications in their effectiveness remains conflicted. Proton Pump Inhibitors are one of the most commonly prescribed medications and are particularly often prescribed to cancer patients.•Our study finds that Proton Pump Inhibitors worsen the outcomes of overall survival and increase risk of disease progression in Non-Small Cell Lung Carcinoma.•We hope that this study will enlighten providers to use proton pump inhibitors more judiciously in patients with Non-Small Cell Lung Carcinoma.</description><subject>Cancer</subject><subject>Immune checkpoint inhibitors</subject><subject>Non- small cell lung cancer</subject><subject>Proton pump inhibitor</subject><subject>Survival outcomes</subject><subject>Systematic Review / Meta-analysis</subject><issn>2049-0801</issn><issn>2049-0801</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kctu3CAUhq2qVROleYEuKpbdeMrF-FJVlaKol0iRuskencGHDFMDLuBE8yB932JNGk033QAHvvMD_19VbxndMMraD_sNuLRsOOW8bIhO8hfVOafNUNOespcn67PqMqU9pZRRKdq2f12dCdmWsmvPq983bgadSTBkjiEHX8-Lm4n1O7u1OcREgid5hwSNsRr0YSWtc4tHoneof87B-nzKW098kUkOpoloLMO0-HuiwWuMH8kVSYeU0UG2mkR8sPhIwI_EYYYaPEyHZNOb6pWBKeHl03xR3X39cnf9vb798e3m-uq21o2UuRaybwRDlE1rOEMq2NB0OLaiET0Ko8VIoRMMkOkBhi0d9CB4LwyVtJdmKy6qz0fZedk6HDX6HGFSc7QO4kEFsOrfE2936j48qIGxoee0CLx_Eojh14IpK2fT-mfwGJakeLGbF67rC8qPqI4hpYjm-RpG1Zqo2qs1UbUmqo6JlqZ3pw98bvmbXwE-HQEsLhUvo0raYnF6tBF1VmOw_9P_A047tS8</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>Dar, Sophia</creator><creator>Merza, Nooraldin</creator><creator>Rahim, Mehek</creator><creator>Qatani, Ahmad</creator><creator>Varughese, Tony</creator><creator>Mohammad, Asna</creator><creator>Masood, Fahad</creator><creator>Reza, Fizza</creator><creator>Shucenwan</creator><creator>Almas, Talal</creator><creator>Ellahi, Aayat</creator><creator>Ligresti, Rosario</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8867-600X</orcidid><orcidid>https://orcid.org/0000-0002-5687-9371</orcidid><orcidid>https://orcid.org/0000-0001-9697-7542</orcidid><orcidid>https://orcid.org/0000-0003-0242-6008</orcidid><orcidid>https://orcid.org/0000-0002-5874-3312</orcidid><orcidid>https://orcid.org/0000-0002-2843-9432</orcidid></search><sort><creationdate>20220601</creationdate><title>Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis</title><author>Dar, Sophia ; Merza, Nooraldin ; Rahim, Mehek ; Qatani, Ahmad ; Varughese, Tony ; Mohammad, Asna ; Masood, Fahad ; Reza, Fizza ; Shucenwan ; Almas, Talal ; Ellahi, Aayat ; Ligresti, Rosario</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-358431ee546f21e031947ed63438e3fc3d0a731ae1c9a9b09c93283f05085fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cancer</topic><topic>Immune checkpoint inhibitors</topic><topic>Non- small cell lung cancer</topic><topic>Proton pump inhibitor</topic><topic>Survival outcomes</topic><topic>Systematic Review / Meta-analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dar, Sophia</creatorcontrib><creatorcontrib>Merza, Nooraldin</creatorcontrib><creatorcontrib>Rahim, Mehek</creatorcontrib><creatorcontrib>Qatani, Ahmad</creatorcontrib><creatorcontrib>Varughese, Tony</creatorcontrib><creatorcontrib>Mohammad, Asna</creatorcontrib><creatorcontrib>Masood, Fahad</creatorcontrib><creatorcontrib>Reza, Fizza</creatorcontrib><creatorcontrib>Shucenwan</creatorcontrib><creatorcontrib>Almas, Talal</creatorcontrib><creatorcontrib>Ellahi, Aayat</creatorcontrib><creatorcontrib>Ligresti, Rosario</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of medicine and surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dar, Sophia</au><au>Merza, Nooraldin</au><au>Rahim, Mehek</au><au>Qatani, Ahmad</au><au>Varughese, Tony</au><au>Mohammad, Asna</au><au>Masood, Fahad</au><au>Reza, Fizza</au><au>Shucenwan</au><au>Almas, Talal</au><au>Ellahi, Aayat</au><au>Ligresti, Rosario</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis</atitle><jtitle>Annals of medicine and surgery</jtitle><addtitle>Ann Med Surg (Lond)</addtitle><date>2022-06-01</date><risdate>2022</risdate><volume>78</volume><spage>103752</spage><epage>103752</epage><pages>103752-103752</pages><artnum>103752</artnum><issn>2049-0801</issn><eissn>2049-0801</eissn><abstract>Immune checkpoint inhibitors (ICI) is a rapidly evolving treatment modality for stage IV non-small cell lung cancer (NSCLC). Concomitant proton pump inhibitor (PPI) use can potentially reduce the clinical efficacy of ICIs; however, the consensus in recent literature has been conflicting. This study aims to analyze overall survival (OS) and progression-free survival (PFS) outcomes in patients with NSCLC on ICI and concomitant PPI therapy. A literature search was done in 3 databases (Pubmed/Medline, Embase, and Cochrane Central). All studies meeting the inclusion criteria assessing the impact of PPIs on the efficacy of ICI in NSCLC patients were systematically identified. A random-effects network meta-analysis evaluated OS and PFS in the two arms. Four studies with 2,940 patients are included in our analysis. ICI usage alone was associated with significantly better OS [HR = 1.46, 95% CI = 1.27–1.67, P &lt; 0.00001] and PFS [HR = 1.31, 95% CI = 1.17–1.47, P &lt; 0.00001] when compared to concomitant PPI and ICI therapy. The concomitant use of PPIs during ICI therapy significantly worsens clinical outcomes with shorter OS and increased risk of disease progression in patients with NSCLC. •Immune checkpoint inhibitors are a rapidly evolving treatment regime used for various cancer therapies. The role of other medications in their effectiveness remains conflicted. Proton Pump Inhibitors are one of the most commonly prescribed medications and are particularly often prescribed to cancer patients.•Our study finds that Proton Pump Inhibitors worsen the outcomes of overall survival and increase risk of disease progression in Non-Small Cell Lung Carcinoma.•We hope that this study will enlighten providers to use proton pump inhibitors more judiciously in patients with Non-Small Cell Lung Carcinoma.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>35600176</pmid><doi>10.1016/j.amsu.2022.103752</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-8867-600X</orcidid><orcidid>https://orcid.org/0000-0002-5687-9371</orcidid><orcidid>https://orcid.org/0000-0001-9697-7542</orcidid><orcidid>https://orcid.org/0000-0003-0242-6008</orcidid><orcidid>https://orcid.org/0000-0002-5874-3312</orcidid><orcidid>https://orcid.org/0000-0002-2843-9432</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2049-0801
ispartof Annals of medicine and surgery, 2022-06, Vol.78, p.103752-103752, Article 103752
issn 2049-0801
2049-0801
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9119820
source ScienceDirect (Online service); PubMed Central
subjects Cancer
Immune checkpoint inhibitors
Non- small cell lung cancer
Proton pump inhibitor
Survival outcomes
Systematic Review / Meta-analysis
title Impact of proton-pump inhibitors on the efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T21%3A03%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20proton-pump%20inhibitors%20on%20the%20efficacy%20of%20immune%20checkpoint%20inhibitors%20in%20non-small%20cell%20lung%20cancer:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=Annals%20of%20medicine%20and%20surgery&rft.au=Dar,%20Sophia&rft.date=2022-06-01&rft.volume=78&rft.spage=103752&rft.epage=103752&rft.pages=103752-103752&rft.artnum=103752&rft.issn=2049-0801&rft.eissn=2049-0801&rft_id=info:doi/10.1016/j.amsu.2022.103752&rft_dat=%3Cproquest_pubme%3E2668220378%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c455t-358431ee546f21e031947ed63438e3fc3d0a731ae1c9a9b09c93283f05085fb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2668220378&rft_id=info:pmid/35600176&rfr_iscdi=true